Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Aug;58(2):119-33.
doi: 10.1111/j.1365-2125.2004.02157.x.

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Affiliations
Review

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Bruce Green et al. Br J Clin Pharmacol. 2004 Aug.

Abstract

The prevalence of obesity in the western world is dramatically rising, with many of these individuals requiring therapeutic intervention for a variety of disease states. Despite the growing prevalence of obesity there is a paucity of information describing how doses should be adjusted, or indeed whether they need to be adjusted, in the clinical setting. This review is aimed at identifying which descriptors of body size provide the most information about the relationship between dose and concentration in the obese. The size descriptors, weight, lean body weight, ideal body weight, body surface area, body mass index, fat-free mass, percent ideal body weight, adjusted body weight and predicted normal body weight were considered as potential size descriptors. We conducted an extensive review of the literature to identify studies that have assessed the quantitative relationship between the parameters clearance (CL) and volume of distribution (V) and these descriptors of body size. Surprisingly few studies have addressed the relationship between obesity and CL or V in a quantitative manner. Despite the lack of studies there were consistent findings: (i) most studies found total body weight to be the best descriptor of V. A further analysis of the studies that have addressed V found that total body weight or another descriptor that incorporated fat mass was the preferred descriptor for drugs that have high lipophilicity; (ii) in contrast, CL was best described by lean body mass and no apparent relationship between lipophilicity or clearance mechanism and preference for body size descriptor was found. In conclusion, no single descriptor described the influence of body size on both CL and V equally well. For drugs that are dosed chronically, and therefore CL is of primary concern, dosing for obese patients should not be based on their total weight. If a weight-based dose individualization is required then we would suggest that chronic drug dosing in the obese subject should be based on lean body weight, at least until a more robust size descriptor becomes available.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The percent success of the size descriptor, dependent upon the number of times it was considered in the regression or population pharmacokinetic analysis; n denotes the number of studies in which the size descriptor was evaluated. The error bar on the null model represents the 95% confidence interval. (a) The pharmacokinetic parameter clearance (CL). (b) Volume of distribution (V)
Figure 2
Figure 2
A box plot of log P-values for each drug vs. category of the best descriptor for that drug. Category 1 size descriptors were adjusted body weight (ABW), body surface area (BSA), predicted normal weight (PNWT), ideal body weight (IBW) and lean body weight (LBW) and category 2 were total body weight (TBW), %IBW and body mass index (BMI). (a) The pharmacokinetic parameter clearance (CL). (b) Volume of distribution (V)

Similar articles

Cited by

References

    1. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–43. - PubMed
    1. National Institute of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, MD: US Department of Health and Human Services; 1998. - PubMed
    1. Lurbe E, Alvarez V, Redon J. Obesity, body fat distribution, and ambulatory blood pressure in children and adolescents. J Clin Hypertens. 2001;3:362–7. - PMC - PubMed
    1. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9:326S–334S. - PubMed
    1. World Health Organization Report of a WHO Consultation on Obesity: Preventing and Managing the Global Epidemic. Geneva: WHO; 1998. - PubMed

Substances